Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 4/20 | 0.40 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 2/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.36 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CPA1 | P15085 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5940872 | 1.00 | CHRM1 (0.44) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL27767453 | 1.00 | CHRM1 (0.44) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL15375770 | 1.00 | CHRM1 (0.44) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL3836127 | 1.00 | CHRM1 (0.44) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL715422 | 0.88 | CHRM1 (0.41) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL10735795 | 0.86 | CHRM1 (0.52) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL9363858 | 0.86 | CHRM1 (0.40) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL9737506 | 0.86 | CHRM1 (0.40) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL16750050 | 0.84 | CHRM1 (0.46) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL5131687 | 0.84 | CHRM1 (0.46) | CHRM1AKR1A1CHRM3HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388940-A1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | CODEXIS, INC. (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250346870-A1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | CODEXIS INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-20250304924-A1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | CODEXIS INC (US) | 2025-10-02 | — | — | US | disclosed |
| US-12421532-B2 | Polynucleotides encoding engineered imine reductases | CODEXIS, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-12378533-B2 | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds | CODEXIS, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| US-12312609-B2 | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds | CODEXIS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-20250137019-A1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | CODEXIS INC (US) | 2025-05-01 | — | — | US | disclosed |
| US-12215368-B2 | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds | CODEXIS, INC. (US) | 2025-02-04 | — | — | US | disclosed |
| US-20240254457-A1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | CODEXIS, INC. (US) | 2024-08-01 | — | — | US | disclosed |
| US-20240228982-A9 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2024-07-11 | — | — | US | disclosed |
| EP-1380590-A1 | Method for synthesis of perindopril and its pharmaceutically acceptable salts | Les Laboratoires Servier (FR) | 2004-01-14 | — | — | EP | disclosed |
| EP-1371659-A1 | Method for synthesis of perindopril and its pharmaceutically acceptable salts [2003/26] | Les Laboratoires Servier (FR) | 2003-12-17 | — | — | EP | disclosed |
| EP-1367063-A1 | Method for synthesis of perindopril and its pharmaceutically acceptable salts | Les Laboratoires Servier (FR) | 2003-12-03 | — | — | EP | disclosed |
| EP-1367062-A1 | Method for synthesis of perindopril and its pharmaceutically acceptable salts | Les Laboratoires Servier (FR) | 2003-12-03 | — | — | EP | disclosed |
| EP-1367061-A1 | Method for synthesis of perindopril and its pharmaceutically acceptable salts | Les Laboratoires Servier (FR) | 2003-12-03 | — | — | EP | disclosed |
| EP-1362845-A2 | New process for the synthesis of N-((S)-1-carboxybutyl)-(S)-alanine esters and their use in the synthesis of perindopril | Les Laboratoires Servier (FR) | 2003-11-19 | — | — | EP | disclosed |
| EP-1362864-A1 | Method for synthesis of perindopril and its pharmaceutically acceptable salts | Les Laboratoires Servier (FR) | 2003-11-19 | — | — | EP | disclosed |
| EP-1362845-A2 | New process for the synthesis of N-((S)-1-carboxybutyl)-(S)-alanine esters and their use in the synthesis of perindopril | Les Laboratoires Servier (FR) | 2003-11-19 | — | — | EP | disclosed |
| EP-1321471-A1 | Method for synthesis of perindopril and its pharmaceutically acceptable salts | LES LABORATOIRES SERVIER (FR) | 2003-06-25 | — | — | EP | disclosed |
| EP-1256590-A1 | Method for synthesis of (2S,3aS,7aS)-1-(S)-alanyl-octahydro-1H-indole-2- carboxylic acid derivatives and use in the synthesis of perindopril | Les Laboratoires Servier S.A. (FR) | 2002-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346870-A1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | AKR1C4, AKR7A2, AKR1C2 | CHRM1 3942/4885AKR1A1 7/4885CHRM3 3814/4885 |
| US-20250388940-A1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | DCXR, PDXK, XDH | CHRM1 1958/4885AKR1A1 35/4885CHRM3 2481/4885 |
| US-12378533-B2 | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds | AKR1C4, AKR7A2, AKR1C2 | CHRM1 3942/4885AKR1A1 7/4885CHRM3 3814/4885 |
| US-20240228982-A9 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | AKR1C4, AKR7A2, AKR1C2 | CHRM1 3942/4885AKR1A1 7/4885CHRM3 3814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.